Search Results - "Denot, C."

Long-Acting Octreotide and Prolonged-Release Lanreotide Formulations Have Different Pharmacokinetic Profiles by Astruc, Beatrice, Marbach, Peter, Bouterfa, Hakim, Denot, Caroline, Safari, Mitra, Vitaliti, Alessandra, Sheppard, Michael

“…Single‐dose pharmacokinetic (PK) profiles and multiple‐dose PK modeling were compared for long‐acting octreotide (20 or 60 mg) and prolonged‐release lanreotide…”
Get full text

SAT2 SODIUM OXYBATE, A BREAKTHROUGH TREATMENT OF ALCOHOL WITHDRAWAL SYNDROME AND MAINTENANCE OF ALCOHOL ABSTINENCE (D&A) by Lesch, O., Skala, K., Addolorato, G., Caputo, F., Ceccanti, M., Djurkowski, M., Filipecka, E., Habrat, B., Horodnicki, J., Pini, L. A., Platz, W., Spazzapan, B., Walter, H., Florkowski, A., Gerra, G., Holzbach, R., Zblowska, H., Bernardi, M., Cacciaglia, R., Vivet, P., Lesch, O. M., Pross, N., Denot, C., Patat, A., Nava, F., Bravin, S., Borroni, G., Bosticco, E., Affini, G. F., Gasparini, G. L., Manzato, E., Thoux, M., Torriani, M., Richini, M., Lucchini, A.

Get full text